No clear answers on mesh for prolapse surgery

A US trial fails to clarify its superiority to hysterectomy
Reuters Health

Transvaginal mesh hysteropexy has not been shown to be superior to vaginal hysterectomy for treatment of uterovaginal prolapse in a randomised clinical trial.

US investigators report three-year outcomes for a group of postmenopausal women (mean age 66) with symptomatic uterovaginal prolapse who underwent vaginal mesh hysteropexy (88 women) or vaginal hysterectomy with uterosacral ligament suspension (87 women) as part of the SUPeR trial conducted at nine centers.